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 For patients with asthma who remain uncontrolled despite inhaled corticosteroid (ICS) therapy, a long-
acting inhaled  b 2 -agonist (LABA) may be added. 1,2 
Combination therapy improves symptoms, reduces 
severe exacerbation rate and achieves better asthma 
control in more patients than ICS monotherapy. 1,3-5 
However, poor adherence to bid therapy may account 
for poor asthma control in some patients. For these 
patients, once-daily therapy could offer them greater 
convenience, thereby improving adherence. 6 
 Vilanterol (VI) (GW642444M) is a LABA with inher-
ent 24-h activity in development as a once-daily treat-
ment in combination with the novel ICS ﬂ uticasone 
furoate (FF) for asthma and COPD. Three dose-ranging 
 Background:  The combination of ﬂ uticasone furoate (FF), a novel inhaled corticosteroid (ICS), 
and vilanterol (VI), a long-acting  b 2 agonist, is under development as a once-daily treatment of 
asthma and COPD. The aim of this study was to compare the efﬁ cacy of FF/VI with ﬂ uticasone 
propionate (FP)/salmeterol (SAL) in patients with persistent asthma uncontrolled on a medium 
dose of ICS. 
 Methods:  In a randomized, double-blind, double-dummy, parallel group study, 806 patients received 
FF/VI (100/25  m g, n  5 403) once daily in the evening delivered through ELLIPTA (GlaxoSmithKline) 
dry powder inhaler, or FP/SAL (250/50  m g, n  5 403) bid through DISKUS/ACCUHALER 
(GlaxoSmithKline). The primary efﬁ cacy measure was 0- to 24-h serial weighted mean (wm) FEV 1 
after 24 weeks of treatment. 
 Results:  Improvements from baseline in 0- to 24-h wmFEV 1 were observed with both FF/VI (341 mL) 
and FP/SAL (377 mL); the adjusted mean treatment difference was not statistically signiﬁ cant 
( 2 37 mL; 95% CI,  2 88 to 15,  P  5 0.162). There were no differences between 0- to 4-h serial wmFEV 1 , 
trough FEV 1 , and asthma control and quality-of-life questionnaire scores. There was no differ-
ence in reported exacerbations between treatments. Both treatments were well tolerated, with no 
clinically relevant effect on urinary cortisol excretion or vital signs and no treatment-related serious 
adverse events. 
 Conclusions:  The efﬁ cacy of once-daily FF/VI was similar to bid FP/SAL in improving lung func-
tion in patients with persistent asthma. No safety issues were identiﬁ ed. 
 Trial registry:  ClinicalTrials.gov; No.: NCT01147848; URL: www.clinicaltrials.gov 
  CHEST 2013; 144(4):1222–1229 
 Abbreviations:  AE  5 adverse event; AQLQ 1 12  5 Asthma Quality of Life  1 12 Questionnaire; EQ-5D  5 European 
Quality of Life-5 Dimensions; FF  5 ﬂ uticasone furoate; FP  5 ﬂ uticasone propionate; ICS  5 inhaled corticosteroid; 
LABA  5 long-acting  b 2 -agonist; SAE  5 serious adverse event; SAL  5 salmeterol; UC  5 urinary cortisol; VI  5 vilanterol; 
wm  5 weighted mean 
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the Declaration of Helsinki and Good Clinical Practice guidelines. 
All patients gave written informed consent. 
 Study Design and Treatments 
 This phase 3, multicenter, randomized, double-blind, double-
dummy, parallel group study was conducted between June 16, 
2010, and July 27, 2011. After screening, eligible patients entered 
a 4-week run-in period during which they replaced their current 
asthma medication with FP 250  m g bid, and their short-acting 
bronchodilator with albuterol delivered through a metered-
dose inhaler. After the run-in period, patients received (1:1) either 
FF/VI 100/25  m g (emitted dose, 92/22  m g) once daily in the even-
ing, administered through an ELLIPTA dry powder inhaler 
(GlaxoSmithKline), or FP/SAL 250/50  m g bid (morning and evening) 
through DISKUS/ACCUHALER (GlaxoSmithKline) for 24 weeks. 
The central randomization schedule was generated by the sponsor 
with a validated computerized system (RandAll; GlaxoSmithKline). 
Patients were randomized by the Registration and Medication Order-
ing System. Neither the patients nor the investigator knew which 
study medication the patient was receiving. A summary of permitted 
and prohibited medications is provided in e-Appendix 2. Compli-
ance with study medication was measured by reviewing the dose 
counter on the dry powder inhaler and DISKUS/ACCUHALER. 
 Outcome Measurements 
 The primary end point was change from baseline in 0- to 24-h 
serial weighted mean (wm) FEV 1 after 24 weeks of treatment. Sec-
ondary end points were individual serial FEV 1 assessments at 
week 24 (FEV 1 at each time point on day 168), time to onset of 
bronchodilator effect (the time point when FEV 1 ﬁ rst exceeded 
the 12% and 200-mL increase over baseline [taken from serial mea-
surements]) at randomization visit only, 0- to 4-h serial wmFEV 1 
postdose at the randomization visit and at week 24, percentage of 
patients experiencing a   12% and   200-mL increase from base-
line in FEV 1 at 12 and 24 h at week 24, and change from baseline 
in clinic visit trough (prebronchodilator and predose) FEV 1 at 
week 24. 
 Other efﬁ cacy end points were scores on the Asthma Quality of 
Life  1 12 Questionnaire (AQLQ 1 12), the Asthma Control Test, 
and the European Quality of Life-5 Dimensions (EQ-5D) test, 
and unscheduled health-care resource utilization. Patients were 
asked to complete questionnaires at baseline and end of treatment. 
A post hoc analysis of the individual AQLQ 1 12 domains and min-
imally important difference (  0.5-point improvement in AQLQ 1 
12 score) was also performed. Results from this analysis are shown 
in e-Appendix 3. 
 Safety Evaluations 
 Adverse events (AEs) could be reported throughout the study. 
Other safety assessments were 24-h urinary cortisol (UC) excre-
tion at baseline and at the end of the 24-week treatment period 
(subset of patients); vital signs (diastolic and systolic BP, pulse rate); 
incidence of severe asthma exacerbations; liver safety; and ECG, 
clinical chemistry, and hematology screening assessments. 
 Patients were withdrawn from the study because of lack of efﬁ -
cacy if they experienced a severe exacerbation or worsening of 
asthma or at the investigator’s discretion. A severe exacerbation was 
deﬁ ned as deterioration of asthma requiring treatment with sys-
temic or oral corticosteroids for   3 days or an inpatient hospitaliza-
tion or ED visit that required systemic corticosteroids. Worsening 
asthma was deﬁ ned as a requirement for any treatment other than 
study medication or use of rescue albuterol. Severe asthma exac-
erbations were not recorded as an AE unless they met the deﬁ ni-
tion of a serious adverse event (SAE). 
FF studies in patients with persistent asthma showed 
signiﬁ cant improvements from baseline in lung func-
tion relative to placebo, with the 100 and 200  m g doses 
of FF (over 8 weeks) providing optimal efﬁ cacy with 
an acceptable tolerability proﬁ le. 7-9 A VI dose-ranging 
study with concurrent ICS, also in persistent asthma, 
showed that the 25- m g dose of VI administered once 
daily over 4 weeks provided the most beneﬁ cial ther-
apeutic ratio. 10 
 The main aim of the current study was to compare 
the efﬁ cacy of FF/VI 100/25  m g administered once daily 
in the evening with ﬂ uticasone propionate (FP)/sal-
meterol (SAL) 250/50  m g administered bid over a 
24-week treatment period in patients aged   12 years 
with persistent asthma uncontrolled on medium-dose 
of ICS. The dose of FP/SAL selected was considered 
suitable for the patient population to be studied. 
 Materials and Methods 
 Patients 
 Patients aged   12 years with asthma 1 were eligible if they could 
demonstrate a   12% and   200-mL reversibility of FEV 1 follow-
ing albuterol inhalation at screening and had a best evening FEV 1 
of 40% to 85% of the predicted normal value at screening and at 
randomization. 11 Before screening, patients had been taking ICS 
for   12 weeks, with a stable medium dose of ICS (FP 250  m g bid 
or equivalent) for   4 weeks. Key exclusion criteria are outlined 
in e-Appendix 1. The study was approved by the local ethics review 
committees (e-Table 1) and was conducted in accordance with 
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 Results 
 Study Population 
 Patient disposition is shown in  Figure 1 . Most patients 
(89%) in both treatment groups completed the 24-week 
treatment period ( Fig 1 ). Patient demographics and 
baseline lung function are shown in  Table 1 . 
 Efﬁ cacy Assessments 
 Lung Function:  Improvements from baseline in 
0- to 24-h serial wmFEV 1 were seen with both FF/VI 
(341 mL) and FP/SAL (377 mL); however, the adjusted 
mean treatment difference was not statistically sig-
niﬁ cant ( 2 37 mL; 95% CI,  2 88 to 15 mL;  P  5 .162) 
( Fig 2 ). There were no differences in key secondary 
end points, including the change from baseline in indi-
vidual serial FEV 1 assessments over time at week 24. 
These showed sustained 24-h duration of action for 
both once-daily FF/VI and bid FP/SAL at all time 
points ( Fig 3 ). The adjusted mean treatment differ-
ences between FF/VI and FP/SAL ranged from 2 to 
58 mL. No important differences were seen between 
FF/VI vs FP/SAL for the secondary end points of time to 
onset of bronchodilator effect, 0- to 4-h serial wmFEV 1 
postdose at randomization and at week 24, percentage 
 Statistical Analysis 
 Sample size calculations were based on the primary end point 
of 0- to 24-h serial wmFEV 1 at the end of the 24-week treatment 
period for the treatment comparison of FF/VI 100/25  m g once 
daily vs FP/SAL 250/50  m g bid. It was estimated that approximately 
348 patients with evaluable data per treatment group would pro-
vide 90% power to detect a difference of 80 mL between FF/VI 
100/25  m g and FP/SAL 250/50  m g; this assumed an SD of 325 mL. 
Details about the analysis populations and power calculation are 
provided in e-Appendix 4. 
 The primary analysis was performed on the intention-to-treat 
population with an analysis of covariance model allowing for the 
effects of baseline FEV 1 , region, sex, age, and treatment group. A 
two-sided 5% risk (signiﬁ cance level) associated with incorrectly 
rejecting the null hypothesis was considered acceptable for this 
study. For the secondary and other efﬁ cacy end points, if the sta-
tistical test for the primary end point failed to reject the null hypo-
thesis of no treatment difference at the 0.05 signiﬁ cance level, the 
tests for the secondary and other efﬁ cacy end points were to be 
interpreted as descriptive only. 
 As a consequence of site audits conducted by the study sponsor 
GlaxoSmithKline, concerns about the quality of data supplied 
were identiﬁ ed for two study centers. These centers contributed 
57 patients (7% of enrolled patients) to the study. Because of these 
concerns, analysis of the primary end point was repeated, exclud-
ing the data from these two centers. Results were consistent with 
the primary analysis. The authors and study sponsor are satisﬁ ed 
that the exclusion of data derived from these centers did not mate-
rially change the ﬁ ndings of the study; therefore, we present a com-
plete data set from all the centers. 
 Figure 1. Consolidated Standards of Reporting Trials patient ﬂ ow diagram. AE  5 adverse event; BD  5 
twice daily; FF  5 ﬂ uticasone furoate; FP  5 ﬂ uticasone propionate; ITT  5 intention to treat; OD  5 once 
daily; SAL  5 salmeterol; VI  5 vilanterol.  a Main reason was that patients did not meet inclusion/exclusion 
criteria (n  5 613 [39%]).  b Main reason was that patients did not meet continuation criteria (n  5 103 [7 %]). 
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 Health Outcomes 
 Improvements from baseline in the AQLQ 1 12, 
Asthma Control Test, and EQ-5D asthma health out-
comes assessments were observed for both FF/VI 
and FP/SAL. There was no difference between treat-
ments ( Table 3 ). 
 Safety Assessments 
 The overall incidence of AEs and SAEs reported 
while on treatment are presented in  Table 4 . The most 
frequently occurring AEs reported by both groups 
were nasopharyngitis and headache; treatment-related 
AEs were similar between groups ( Table 4 ). Nine 
patients reported on-treatment SAEs (four receiving 
FF/VI and ﬁ ve receiving FP/SAL) ( Table 4 ). SAEs were 
single events with the exception of asthma exacerbation 
and pneumonia (one pretreatment and one on treat-
ment [FP/SAL]). None of the SAEs was considered 
treatment related. No deaths were reported during the 
study. 
 There was no statistically signiﬁ cant difference 
between FF/VI and FP/SAL in 24-h UC excretion 
at week 24 (adjusted treatment ratio, 0.85; 95% CI, 
0.72-1.02;  P  5 .075) ( Fig 4 ). However, 24-h UC excre-
tion did increase in both groups from baseline to 
week 24 (ratio to baseline, 1.11 and 1.21 for FF/VI and 
FP/SAL, respectively). 
 The incidence of asthma exacerbations was low, and 
there was no difference between groups (3% vs 2% 
on FP/SAL vs FF/VI, respectively [on-treatment events]). 
Eight (2%) patients in the FF/VI group and seven 
(2%) in the FP/SAL group withdrew because of their 
exacerbation. One patient in the FF/VI group and two 
in the FP/SAL group were hospitalized because of their 
exacerbations. None of the exacerbations were consid-
ered treatment related. No clinically relevant treatment 
effects on vital signs (e-Appendix 5) or liver function 
of patients obtaining a   12% and   200-mL increase 
from baseline in FEV 1 at 12 and 24 h at week 24, and 
change from baseline in clinic visit trough (prebron-
chodilator and predose) FEV 1 at week 24 ( Table 2 ). 
Change from baseline in predose FEV 1 over the 24-week 
treatment period is shown in e-Figure 1. 
 Table 1— Patient Demographics and Baseline Lung 
Function (Intention-to-Treat Population) 
Characteristic 
FF/VI 100/25  m g 
OD  pm (n  5 403)
FP/SAL 250/50  m g 
bid (n  5 403)
Age, y 43.8   15.9 41.9   16.9
 Range 12-79 12-80
Female sex 244 (61) 245 (61)
Race
 White 242 (60) 232 (58)
 Asian 124 (31) 125 (31)
 Black/African heritage 36 (9) 43 (11)
 Other a 1 ( , 1) 3 ( , 1)
Percent reversibility 
 of FEV 1 , b L
26.4   14.4 29.0   18.0
Predose FEV 1 , L 2.011   0.639 2.048   0.625
FEV 1  % predicted 68.0   11.7 68.8   11.0
ICS use c at screening 125 (31) 123 (31)
ICS/LABA use at 
 screening
279 (69) 279 (69)
Data are presented as mean   SD or No. (%) unless otherwise indi-
cated. FF  5 ﬂ uticasone furoate; FP  5 ﬂ uticasone propionate; ICS  5 
inhaled corticosteroid; LABA  5 long-acting  b 2 -agonist; OD  5 once daily; 
SAL  5 salmeterol; VI  5 vilanterol.
 a Native Hawaiian or other Paciﬁ c Islander, African American/African 
heritage and white .
 b Measured at screening.
 c Patients needed to have been maintained on a medium dose of ICS 
(eg, FP 250  m g bid) for   4 wk before screening.
 Figure 2. Adjusted means for 0- to 24-h serial weighted mean 
FEV 1 at week 24 (intention-to-treat population). LS  5 least squares. 
See Figure 1 legend for expansion of other abbreviations. 
 Figure 3. Adjusted mean change from baseline in FEV 1 over 
time at week 24 for FF/VI dosed OD in the evening and FP/SAL 
dosed BD (intention-to-treat population). See Figure 1 and 2 leg-
ends for expansion of abbreviations. 
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toms. 2 A number of studies have shown that nonadher-
ence to asthma therapy is an important reason for loss 
of asthma control in some patients. 14-16 Adherence to 
the treatment schedule was high during the study 
( . 94% in both groups), although the artiﬁ cial setting 
of a clinical trial may have encouraged normally non-
adherers to take their medication. If poor adherence 
to the dosing schedule is an important factor in loss of 
asthma control, then once-daily dosing (as opposed to 
bid dosing) such as that provided by FF/VI may rep-
resent a more-convenient treatment option for patients 
in a real-world setting. 17 
 No differences in Asthma Control Test scores or in 
measures of quality of life (AQLQ 1 12 and EQ-5D) 
were shown in the present study. A difference of 1.4 
was observed between groups on the EQ-5D test, 
but this difference was not statistically signiﬁ cant. The 
outcomes of the post hoc analysis (e-Appendix 3) suggest 
that FF/VI may provide clinically relevant improve-
ments in certain patient-reported quality-of-life mea-
sures (environmental domain of the AQLQ 1 12 in the 
present study), as well as in the percentage of patients 
who improved by at least the minimally important dif-
ference of 0.5, 18 that were not reported with FP/SAL. 
However, this statement is speculative and requires 
further evaluation in real-world studies outside the 
environment of a clinical trial. 
parameters were found, with the exception of one 
patient in the FP/SAL group who met liver stopping 
criteria of alanine aminotransferase levels more than 
eight times the upper limit of normal, which was 
reported as an AE but was not considered treatment 
related. 
 Discussion 
 In this study of patients aged   12 years with per-
sistent asthma uncontrolled on a medium dose of ICS, 
FF/VI 100/25  m g once daily in the evening was not 
signiﬁ cantly different from FP/SAL 250/50  m g bid for 
the primary end point of 0- to 24-h serial wmFEV 1 at 
week 24 or for any of the secondary end points. The 
AE proﬁ les for both treatments were similar, and those 
AEs reported with FP/SAL were consistent with those 
previously reported with this drug combination. 12,13 
 Patients were symptomatic on a medium dose of 
ICS at baseline. According to current asthma guidelines, 
these patients would require a step up in their asthma 
treatment from step 3 to 4. 2 Lack of asthma control in 
the patient population at baseline was evident by an 
FEV 1 of approximately 68% of the predicted normal 
value for both groups and by the fact that   50% of 
patients had an Asthma Control Test score of  , 20. The 
goal of asthma treatment is to control asthma symp-
 Table 2— Secondary End Points a 
Secondary End Point Treatment Value
Difference FF/VI OD  pm vs FP/SAL bid, 
(95% CI)
Time to onset of bronchodilator effect (median time to   12% 
 and   200 mL FEV 1 over baseline at randomization visit), min
0.948 b (0.797 to 1.128)
 FF/VI 61
 FP/SAL 59
0- to 4-h serial wmFEV 1 postdose at randomization visit, L  2 0.030 ( 2 0.071 to 0.012)
 FF/VI 0.316   0.0149
 FP/SAL 0.346   0.0149
0- to 4-h serial wmFEV 1 postdose at week 24, L  2 0.034 ( 2 0.086 to 0.017)
 FF/VI 0.360   0.0184
 FP/SAL 0.394   0.0186
% patients obtaining   12% and   200 mL increase from baseline 
 in FEV 1 at 12 h and at 24 h at week 24
 12-h FF/VI 56 1.31 c (0.96 to 1.78)
 12-h FP/SAL 50 …
 24-h FF/VI 51 1.09 c (0.80 to 1.48)
 24-h FP/SAL 50 …
Change from baseline in clinic visit trough (prebronchodilator and 
 predose) FEV 1 at week 24
 2 0.019 ( 2 0.073 to 0.034)
 FF/VI 0.281   0.0191
 FP/SAL 0.300   0.0193
Data are presented as least squares mean   SE change from baseline unless otherwise indicated. Intention-to-treat population, n  5 403 (FF/VI 
100/25  m g OD  pm) and n  5 403 (FP/SAL 250  m g bid). HR  5 hazard ratio; wm  5 weighted mean. See Table 1 legend for expansion of other 
abbreviations.
 a Results are for all secondary end points other than the end point individual serial FEV 1 assessments at week 24 (see  Fig 3 ).
 b HR.
 c OR.
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In the present study, no clinically relevant effects of 
FF/VI or FP/SAL were found in measures of BP or 
pulse rate. 
 It may be considered a limitation that the study 
duration was too short to reliably collect information 
on important end points such as exacerbations. Also, 
while a once-daily dosing schedule could provide greater 
convenience to the patient and may therefore increase 
compliance to treatment, 23 the double-blind, double-
dummy nature of the study, together with the very 
high compliance levels during the study, means that 
the full beneﬁ t of once-daily dosing compared with 
bid dosing could not be realized in this study. This 
can only be investigated in a real-world effectiveness 
study, such as the Salford Lung Study, which is now 
under way. 24 It is possible that prestudy ICS adher-
ence was lower than anticipated by the protocol, as 
suggested by the high degree of FEV 1 reversibility seen 
at screen ing. Patient compliance with run-in medica-
tion was not formally assessed. Once-daily FF/VI had 
similar treatment effects to bid FP/SAL in improving 
lung function and health status in this double-blind 
 FF/VI and FP/SAL were well tolerated, and FF/VI 
had a similar AE proﬁ le to FP/SAL. The AE proﬁ le 
with FF/VI reported in the present study is consistent 
with that seen in the two FF dose-ranging studies that 
included the 100  m g once-daily dose 7,8 and the two stud-
ies of VI 25  m g plus concurrent ICS. 10,19 Most of the 
SAEs reported in the present study were single events, 
and none were considered treatment related. Asthma 
exacerbations requiring hospitalization occurred in 
one patient receiving FF/VI and two patients receiv-
ing FP/SAL. 
 A potential effect of ICS treatment is reduction in UC 
levels as a result of suppression of the hypothalamic-
pituitary-adrenal axis, although this usually only occurs 
at higher doses of ICS. 9,20,21 In earlier phase dose-
ranging studies, once-daily FF 100 or 200  m g did not 
signiﬁ cantly inhibit 24-h UC levels relative to placebo. 7,8 
In the current study, clinically insigniﬁ cant increases 
in UC levels from baseline were reported, and no sta-
tistically signiﬁ cant differences were observed between 
the groups at week 24. LABAs have occasional side 
effects, such as headache, tremor, and hypertension. 22 
 Table 3— Health Outcomes Assessments 
Assessment
Mean Score at 
Baseline
Mean Score at 
Week 24
LS Mean Change   SE 
From Baseline a 
Difference FF/VI OD  pm 
vs FP/SAL bid, (95% CI) a 
AQLQ 1 12 (total score) 0.09 ( 2 0.03 to 0.21)
 FF/VI 5.35 5.85 0.46   0.043
 FP/SAL 5.37 5.79 0.37   0.043
ACT 0.2 ( 2 0.2 to 0.7)
 FF/VI 18.9 21.2 2.3   0.16
 FP/SAL 18.8 20.9 2.0   0.16
EQ-5D dimensions, % reporting no problems
 Mobility N/A 1.37 b (0.86 to 2.18)
  FF/VI
  FP/SAL 83 85
 Self-care 83 84 N/A 1.14 b (0.38 to 3.41)
  FF/VI 97 98
  FP/SAL 98 98
 Usual activities N/A 1.44 b (0.93 to 2.24)
  FF/VI 75 84
  FP/SAL 74 82
 Pain/discomfort N/A 1.12 b (0.80 to 1.58)
  FF/VI 67 69
  FP/SAL 60 66
 Anxiety/depression N/A 0.79 b (0.52 to 1.19)
  FF/VI 78 77
  FP/SAL 77 81
EQ-5D VAS score
 VAS score 1.4 ( 2 0.3 to 3.0)
  FF/VI 80.4 85.6 5.5   0.60
  FP/SAL 80.0 84.2 4.1   0.60
Intention-to-treat population, n  5 403 (FF/VI 100/25  m g OD  pm) and n  5 403 (FP/SAL 250  m g bid). ACT  5 Asthma Control Test; AQLQ 1 12  5 Asthma 
Quality of Life  1 12 Questionnaire; EQ-5D  5 European Quality of Life-5 Dimensions; N/A  5 not applicable; VAS  5 visual analog scale. See Table 
1 legend for expansion of other abbreviations.
 a AQLQ 1 12, ACT, and EQ-5D VAS score, analysis of covariance was used, with covariates of baseline score, country, sex, age, and treatment; EQ-5D, 
logistic regression analysis was used, with covariates of baseline, region, sex, age, and treatment.
 b OR. 
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there was no difference in efﬁ cacy or safety between 
FF/VI 100/25  m g administered once daily in the eve-
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 Table 4— On-Treatment AEs   3% in Any Treatment 
Group, All SAEs, and Treatment-Related AEs 
(Intention-to-Treat Population) 
Event
FF/VI 100/25  m g 
OD  pm (n  5 403)
FP/SAL 250/50  m g 
bid (n  5 403)
Any event 213 (53) 198 (49)
 Nasopharyngitis 46 (11) 46 (11)
 Headache 34 (8) 41 (10)
 URTI 26 (6) 16 (4)
 Cough 15 (4) 13 (3)
 Back pain 11 (3) 11 (3)
 Oropharyngeal pain 11 (3) 9 (2)
 Sinusitis 12 (3) 7 (2)
 Pyrexia 13 (3) 5 (1)
 Productive cough 11 (3) 5 (1)
Treatment-related AEs (any) 19 (5) 15 (4)
 SAEs
  Any event 4 ( , 1) 5 (1)
  Pneumonia 0 1 ( , 1)
  URTI 1 ( , 1) 0
  Urinary tract infection 0 1 ( , 1)
  Asthma 1 ( , 1) 2 ( , 1)
  Myocardial ischemia 1 ( , 1) 0
  Cholelithiasis 1 ( , 1) 0
  CO poisoning 0 1 ( , 1)
  Disorientation 0 1 ( , 1)
 Treatment-related SAEs 
  (any)
0 0
Data are presented as No. (%). AE  5 adverse event; SAE  5 serious 
adverse event; URTI  5 upper respiratory tract infection. See Table 1 
legend for expansion of other abbreviations.
 Figure 4. Adjusted ratios to baseline for 24-h urinary cortisol 
excretion at week 24 (urinary cortisol population). See Figure 1 
and 2 legends for expansion of abbreviations. 
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